Journal of Gynecologic Oncology最新文献

筛选
英文 中文
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer. 与卵巢癌患者 PARP 抑制剂疗效相关的肠道微生物群。
IF 3.4 2区 医学
Journal of Gynecologic Oncology Pub Date : 2024-10-21 DOI: 10.3802/jgo.2025.36.e38
Mika Okazawa-Sakai, Shunsuke A Sakai, Ichinosuke Hyodo, Satoshi Horasawa, Kentaro Sawada, Takao Fujisawa, Yasuko Yamamoto, Shogen Boku, Yoh Hayasaki, Masanori Isobe, Daisuke Shintani, Kosei Hasegawa, Tomomi Egawa-Takata, Kimihiko Ito, Kei Ihira, Hidemichi Watari, Kazuhiro Takehara, Hiroshi Yagi, Kiyoko Kato, Tatsuyuki Chiyoda, Kenichi Harano, Yoshiaki Nakamura, Riu Yamashita, Takayuki Yoshino, Daisuke Aoki
{"title":"Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.","authors":"Mika Okazawa-Sakai, Shunsuke A Sakai, Ichinosuke Hyodo, Satoshi Horasawa, Kentaro Sawada, Takao Fujisawa, Yasuko Yamamoto, Shogen Boku, Yoh Hayasaki, Masanori Isobe, Daisuke Shintani, Kosei Hasegawa, Tomomi Egawa-Takata, Kimihiko Ito, Kei Ihira, Hidemichi Watari, Kazuhiro Takehara, Hiroshi Yagi, Kiyoko Kato, Tatsuyuki Chiyoda, Kenichi Harano, Yoshiaki Nakamura, Riu Yamashita, Takayuki Yoshino, Daisuke Aoki","doi":"10.3802/jgo.2025.36.e38","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e38","url":null,"abstract":"<p><strong>Objective: </strong>To investigate an association between the gut microbiome and efficacy of poly(ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer.</p><p><strong>Methods: </strong>This study conducted fecal microbiome analysis (16S rRNA gene sequencing) and circulating tumor DNA (ctDNA) profiling for ovarian cancer patients who underwent PARPi maintenance therapy. Fecal and blood samples were collected at the baseline and the progressive disease (PD) or last follow-up. The relative abundance of gut microbes and progression-free survival (PFS) were analyzed using linear discriminant analysis of effect size and the Cox proportional hazard model according to <i>BRCA1</i>/<i>2</i> mutation (<i>BRCA1</i>/<i>2</i>mut) status detected by ctDNA sequencing.</p><p><strong>Results: </strong>Baseline samples were available from 23 <i>BRCA1</i>/<i>2</i>mut-positive patients and 33 <i>BRCA1/2</i>mut-negative patients. The microbes enriched in the baseline samples with long PFS were <i>Bifidobacterium</i>, <i>Roseburia</i>, <i>Dialister</i>, <i>Butyricicoccus</i>, and <i>Bilophila</i> for <i>BRCA1/2</i>mut-positive patients and <i>Phascolarctobacterium</i> for <i>BRCA1/2</i>mut-negative patients. In multivariate analyses dividing patients by the median values of relative abundances, no bacteria were associated with PFS in <i>BRCA1/2</i>mut-positive patients, whereas high <i>Phascolarctobacterium</i> abundances (≥1.11%) was significantly associated with longer PFS in <i>BRCA1/2</i>mut-negative patients (median 14.0 vs. 5.9 months, hazard ratio=0.28; 95% confidence interval=0.11-0.69; p=0.014). In the last samples, the relative abundances of <i>Phascolarctobacterium</i> were significantly higher in patients without PD (n=5) than those with PD (n=15) (median 1.25% vs. 0.06%; p=0.016).</p><p><strong>Conclusion: </strong>High fecal composition of <i>Phascolarctobacterium</i> was associated with prolonged PFS in patients with <i>BRCA1/2</i>mut-negative ovarian cancer receiving PARPi therapy. Our results would provide new insights for future research.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Humanized patient-derived xenograft mouse model bearing ovarian clear cell carcinoma. 卵巢透明细胞癌人源化异种移植小鼠模型。
IF 3.4 2区 医学
Journal of Gynecologic Oncology Pub Date : 2024-10-21 DOI: 10.3802/jgo.2025.36.e40
Zhen Yuan, Huimei Zhou, Dongyan Cao, Jiaxin Yang, Qian Liu
{"title":"Humanized patient-derived xenograft mouse model bearing ovarian clear cell carcinoma.","authors":"Zhen Yuan, Huimei Zhou, Dongyan Cao, Jiaxin Yang, Qian Liu","doi":"10.3802/jgo.2025.36.e40","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e40","url":null,"abstract":"<p><strong>Objective: </strong>The study aimed to establish humanized patient-derived xenograft (PDX) mouse models of ovarian clear cell carcinoma (OCCC) and evaluate their therapeutic responses.</p><p><strong>Methods: </strong>PDX models and their humanized counterparts (CD34+ humanized PDX models) derived from the same tumor source were developed, and the therapeutic responses were compared between the models.</p><p><strong>Results: </strong>Treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor significantly reduced tumor size in traditional OCCC PDX models (p=0.021). Although differences in tumor growth between traditional PDX models and humanized PDX models were observed, they were not statistically significant (p=0.438). However, treatment effects of PI3K inhibitor differed significantly between conventional and humanized mice (p=0.006). In the Humanized PDX cohort, both programmed cell death protein-1 antibody monotherapy and PI3K inhibitor treatment slowed tumor growth relative to controls, with a synergistic effect noted during the latter part of the study, though these effects were not statistically significant.</p><p><strong>Conclusion: </strong>This pioneering study successfully develop a humanized PDX model for OCCC, highlighting differential responses to treatments compared to conventional PDX models.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bevacizumab combined with chemotherapy could be superior to chemotherapy alone in relapsed ovarian cancer after PARPi: evidence from a multi-center propensity score-matched analysis. 对于PARPi治疗后复发的卵巢癌,贝伐单抗联合化疗可能优于单独化疗:一项多中心倾向评分匹配分析的证据。
IF 3.4 2区 医学
Journal of Gynecologic Oncology Pub Date : 2024-10-07 DOI: 10.3802/jgo.2025.36.e36
Lin Zhong, Haixia Wang, Cuirong Lei, Dongling Zou
{"title":"Bevacizumab combined with chemotherapy could be superior to chemotherapy alone in relapsed ovarian cancer after PARPi: evidence from a multi-center propensity score-matched analysis.","authors":"Lin Zhong, Haixia Wang, Cuirong Lei, Dongling Zou","doi":"10.3802/jgo.2025.36.e36","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e36","url":null,"abstract":"<p><strong>Objective: </strong>A retrospective, multi-center propensity score-matched (PMS) analysis was conducted to investigate the efficacy and safety of the treatment strategy that combines bevacizumab and chemotherapy for patients with relapsed epithelial ovarian cancer (EOC) who previously received poly ADP-ribose polymerase inhibitors (PARPis).</p><p><strong>Methods: </strong>A total of 250 ovarian cancer (OC) patients relapsed after PARPi received chemotherapy with or without bevacizumab at 4 medical centers were enrolled in the study. For both treatments, Kaplan-Meier analysis and Cox regression were used to compare PFS.</p><p><strong>Results: </strong>In the multivariable analysis of 250 patients, the incorporation of bevacizumab into chemotherapy demonstrated a significant enhancement in PFS (hazard ratio [HR]=0.49; 95% confidence interval [CI]=0.34-0.72; p<0.001). Fifty-five patients were enrolled in Group A (bevacizumab combined with chemotherapy) and 55 were enrolled in Group B (chemotherapy alone regime) after PSM analysis. A statistically significant difference in PFS was observed between the 2 regimens (HR=0.62; 95% CI=0.40-0.97; p=0.036), suggesting that the bevacizumab combined with chemotherapy regimen confers superior clinical benefits. The median PFS was 11 months in Group A and 9 months in Group B. A significant variation was noted in PFS between patients without RCRS (HR=0.50; 95% CI=0.30-0.82) and the platinum-resistant subgroup (HR=0.31; 95% CI=0.14-0.68). Adverse effects of Grade 3-4 were more prevalent in Group A than in Group B. Additionally, instances of severe hypertension and bowel perforation were reported solely within Group A.</p><p><strong>Conclusion: </strong>In patients diagnosed with EOC relapsed after PARPi, the regime of chemotherapy combined with bevacizumab is associated with better PFS.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic performances of the Ovarian Adnexal Reporting and Data System, the Risk of Ovarian Malignancy Algorithm, and the Copenhagen Index in the preoperative prediction of ovarian cancer: a prospective cohort study. 卵巢附件报告和数据系统、卵巢恶性肿瘤风险算法和哥本哈根指数在卵巢癌术前预测中的诊断性能:一项前瞻性队列研究。
IF 3.4 2区 医学
Journal of Gynecologic Oncology Pub Date : 2024-09-24 DOI: 10.3802/jgo.2025.36.e30
Thi Quynh Nhu Vo, Doan Tu Tran, Tran Thao Nguyen Nguyen, Van Duc Vo, Minh Tam Le, Vu Quoc Huy Nguyen
{"title":"Diagnostic performances of the Ovarian Adnexal Reporting and Data System, the Risk of Ovarian Malignancy Algorithm, and the Copenhagen Index in the preoperative prediction of ovarian cancer: a prospective cohort study.","authors":"Thi Quynh Nhu Vo, Doan Tu Tran, Tran Thao Nguyen Nguyen, Van Duc Vo, Minh Tam Le, Vu Quoc Huy Nguyen","doi":"10.3802/jgo.2025.36.e30","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e30","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the diagnostic performance of the Risk of Ovarian Malignancy Algorithm (ROMA), Copenhagen Index (CPH-I), and Ovarian Adnexal Reporting and Data System (O-RADS) for the preoperative prediction of ovarian cancer (OC).</p><p><strong>Methods: </strong>A prospective cohort study was conducted on 462 patients diagnosed with ovarian tumors admitted to the Departments of Obstetrics and Gynecology, Hue University of Medicine and Pharmacy Hospital, and Hue Central Hospital from May 2020 to December 2022. ROMA and CPH-I were calculated using cancer antigen 125 (CA125), human epididymal protein 4 (HE4) levels, and patient characteristics (age and menopausal status). O-RADS criteria were applied to describe ovarian tumor characteristics from ultrasound findings. Compared with histopathological results, the predictive values of ROMA, CPH-I, and O-RADS alone or in combination with CA125/HE4 for OC were calculated.</p><p><strong>Results: </strong>Among 462 patients, 381 had benign tumors, 11 had borderline tumors, and 50 had OC. At optimal cut-off points, ROMA's and CPH-I's areas under the curves (AUCs) were 0.880 (95% confidence interval [CI]=0.846-0.909) and 0.890 (95% CI=0.857-0.918), respectively, and ROMA and CPH-I sensitivities/specificities (Se/Sp) were 68.85%/95.01% and 77.05%/91.08%, respectively. O-RADS ≥3 yielded an AUCs of 0.949 (95% CI=0.924-0.968), with Se/Sp of 88.52%/88.98% (p<0.001). Combining O-RADS with CA125 demonstrated the highest predictive value, with AUCs of 0.969 (95% CI=0.949-0.983) and Se/Sp of 98.36%/86.09% (p<0.001).</p><p><strong>Conclusion: </strong>The ROMA, CPH-I, O-RADS, O-RADS + CA125, and O-RADS + HE4 models demonstrated good predictive values for OC; the combination of O-RADS and CA125 yielded the highest values.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142348088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of HPV E7/miR-143-3p/SH2D3A pathway in regulating the occurrence and development of cervical cancer. HPV E7/miR-143-3p/SH2D3A 通路在调控宫颈癌发生和发展中的作用。
IF 3.4 2区 医学
Journal of Gynecologic Oncology Pub Date : 2024-09-23 DOI: 10.3802/jgo.2025.36.e34
Meiyao Wu, Renci Liu, Yao Liu, Fan Shen, Yang Zhao, Xiujie Sheng
{"title":"Role of HPV E7/miR-143-3p/SH2D3A pathway in regulating the occurrence and development of cervical cancer.","authors":"Meiyao Wu, Renci Liu, Yao Liu, Fan Shen, Yang Zhao, Xiujie Sheng","doi":"10.3802/jgo.2025.36.e34","DOIUrl":"10.3802/jgo.2025.36.e34","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to explore the role of SH2D3A in cervical cancer, as well as its potential interaction with human papillomavirus (HPV) E7 and microRNA (miRNA).</p><p><strong>Methods: </strong>Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunohistochemistry were used to compare the expressions of SH2D3A in tissues. To assess the effects of SH2D3A on cervical cancer cell phenotypes, SH2D3A was knocked down in SiHa and HeLa cells, followed by cell proliferation (Cell Counting Kit-8 assay), apoptosis (flow cytometry), and invasion (Transwell assay) analyses. A transplantation tumor model was established to compare the tumorigenic ability of cervical cancer cells before and after SH2D3A silencing. Bioinformatics analysis predicted and dual-luciferase reporter assays verified the sponge adsorption effect of SH2D3A on miRNA. Western blot and qRT-PCR analyses were conducted to examine the impact on target genes following the downregulation of HPV E7 and SH2D3A.</p><p><strong>Results: </strong>SH2D3A expression was significantly elevated in cervical cancer tissues. SH2D3A silencing inhibited cell proliferation and invasion, induced apoptosis, and reduced tumorigenesis in nude mice. Bioinformatics tools identified a binding relationship between SH2D3A and miR-143-3p, confirmed by the luciferase reporter assays. Western blot analysis revealed that SH2D3A knockdown led to decreased levels of Janus kinase 1 (JAK1) and signal transducer and activator of transcription 3 (STAT3) proteins. Additionally, qRT-PCR showed that SH2D3A mRNA levels decreased after HPV E7 silencing, whereas miR-143-3p levels significantly increased.</p><p><strong>Conclusion: </strong>HPV E7 influences SH2D3A expression through miR-143-3p, thereby regulating the JAK1/STAT3 pathway. This mechanism promotes the occurrence and development of cervical cancer.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Planning and performing simultaneous bariatric surgery and robotic hysterectomy in a super-obese patient with endometrial cancer. 为一名患有子宫内膜癌的超重患者计划并同时实施减肥手术和机器人子宫切除术。
IF 3.4 2区 医学
Journal of Gynecologic Oncology Pub Date : 2024-09-11 DOI: 10.3802/jgo.2025.36.e32
Hasan Volkan Ege, Murat Cengiz, Nezih Akkapulu, Utku Akgör, Murat Gültekin, Nejat Ozgül, Derman Basaran
{"title":"Planning and performing simultaneous bariatric surgery and robotic hysterectomy in a super-obese patient with endometrial cancer.","authors":"Hasan Volkan Ege, Murat Cengiz, Nezih Akkapulu, Utku Akgör, Murat Gültekin, Nejat Ozgül, Derman Basaran","doi":"10.3802/jgo.2025.36.e32","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e32","url":null,"abstract":"<p><p>Endometrial cancer (EC) is the most common gynecological malignancy in developed countries, and endometrial intraepithelial neoplasia (EIN) is the defined precancerous lesion. Obesity is considered a risk factor for both EC and EIN. On the other hand, mortality is often attributed to obesity-related conditions in patients with early-stage EC. Bariatric surgery has been shown to improve oncological outcomes and obesity-related morbidity and mortality in patients with EC. Therefore, combination surgery addressing both uterine disease and obesity is a very recent point of interest. Here, we present a video article to demonstrate the crucial surgical steps for a simultaneous robotic-assisted total laparoscopic hysterectomy and sleeve gastrectomy in a patient with super obesity and EIN. A patient in her 40s with a body mass index of 62.4 kg/m² and a diagnosis of EIN was scheduled for combo surgery. The operation started with sleeve gastrectomy in the reverse Trendelenburg position. The da Vinci Xi Surgical System™ (Intuitive Surgical Inc., Sunnyvale, CA, USA) with left-side docking was used for surgery. After the mobilization of the stomach, gastric resection was performed using a stapler. Following sleeve gastrectomy, the patient was positioned in the Trendelenburg position, and the robotic system was positioned for hysterectomy. Hysterectomy and salpingectomy were performed. The excised stomach and hysterectomy material were removed through the vagina. A frozen examination revealed EC below 2 cm with superficial invasion, and bilateral oophorectomy was performed. The whole surgery took approximately 4 hours. No postoperative complications occurred, and the patient was discharged on the 3rd day.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142348089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of autophagy related ATG4B gene, protein and miR-655-3p expression levels in endometrial cancer and hyperplasia. 评估子宫内膜癌和子宫内膜增生症中与自噬相关的 ATG4B 基因、蛋白和 miR-655-3p 的表达水平。
IF 3.4 2区 医学
Journal of Gynecologic Oncology Pub Date : 2024-09-09 DOI: 10.3802/jgo.2025.36.e33
Elmira Mahdinia, Rahim Rostami, Azadeh Rezaei, Parvin Ghaderi, Sahar Yarahmadi, Soudabeh Fallah
{"title":"Evaluation of autophagy related ATG4B gene, protein and miR-655-3p expression levels in endometrial cancer and hyperplasia.","authors":"Elmira Mahdinia, Rahim Rostami, Azadeh Rezaei, Parvin Ghaderi, Sahar Yarahmadi, Soudabeh Fallah","doi":"10.3802/jgo.2025.36.e33","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e33","url":null,"abstract":"<p><strong>Objective: </strong>The pathogenesis of endometrial cancer (EC) and hyperplasia is complex and poorly understood. Autophagy has emerged as a crucial aspect of this process.</p><p><strong>Methods: </strong>This study examines the role of autophagy in the pathogenesis of EC and hyperplasia by investigating the expression of the autophagy-related 4B cysteine peptidase (ATG4B) gene, protein, and miR-665-3p levels in patients compared to a control group. This cross-sectional case control study analyzed 90 endometrial tissues, including 30 tumors, 30 normal controls, and 30 hyperplasia, using quantitative reverse transcription polymerase chain reaction and Western blot to assess ATG4B gene and protein levels.</p><p><strong>Results: </strong>Higher ATG4B gene expression levels were found in the endometrial tissue of EC patients than in hyperplasia patients and controls. Furthermore, protein levels of ATG4B were also higher in EC and hyperplasia patients than in controls. ATG4B gene expression and protein levels were positively correlated in EC patients. However, in EC patients, miR-655-3p showed a significant negative correlation with the ATG4B gene and protein levels.</p><p><strong>Conclusion: </strong>ATG4B gene and protein expression is elevated in EC tissue, suggesting their role as a tumor promoter. Evaluating their levels could serve as markers for monitoring EC progression and prognosis.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142289041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modified posterior pelvic exenteration combined with ileocecal resection for locally advanced endometrial cancer. 局部晚期子宫内膜癌的改良盆腔后外展联合回盲部切除术。
IF 3.9 2区 医学
Journal of Gynecologic Oncology Pub Date : 2024-09-02 DOI: 10.3802/jgo.2025.36.e31
Kazuyoshi Kato
{"title":"Modified posterior pelvic exenteration combined with ileocecal resection for locally advanced endometrial cancer.","authors":"Kazuyoshi Kato","doi":"10.3802/jgo.2025.36.e31","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e31","url":null,"abstract":"There are several retrospective studies which have suggested that optimal cytoreductive surgery for stage IV endometrial cancer improves survival [1-3]. In addition, some investigators have reported that achieving maximal cytoreduction to a visibly disease-free outcome in the abdominal cavity for endometrial cancer with distant metastases can extend patients' survival [4]. Due to the anatomic proximity of the rectosigmoid colon to the female pelvic organs and its involvement in locally advanced endometrial cancer, an en bloc resection of the uterus, adnexa, and rectosigmoid, also known as a modified posterior pelvic exenteration (MPPE), is performed to achieve optimal cytoreduction [5,6]. Additionally, if the tumor has infiltrated the ileal end and/or cecum, ileocecal resection can be added. I report the details of the technique for this surgery requiring intestinal reconstruction. We routinely placed a transanal drainage tube after a MPPE to decrease the rate of anastomotic leakage and the need for a diverting stoma [7]. No visible tumors were observed after surgery. No intraoperative or early postoperative complications occurred. The patient did not have an impediment in her postoperative bladder and bowel function. Concerning the extent of hysterectomy during surgery, the procedure was performed as described in that of a class II hysterectomy [8]. This might partly explain the preservation of these function. Subsequently, she was treated with 6 cycles of doxorubicin and cisplatin chemotherapy. Two years after surgery, she is alive with no evidence of recurrence. The patient provided informed consent for use of this video.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":"49 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer. 将替索单抗维多汀作为宫颈癌二线或三线疗法的成本效益。
IF 3.4 2区 医学
Journal of Gynecologic Oncology Pub Date : 2024-09-01 Epub Date: 2024-01-24 DOI: 10.3802/jgo.2024.35.e58
Gengwei Huo, Wenjie Liu, Peng Chen
{"title":"Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer.","authors":"Gengwei Huo, Wenjie Liu, Peng Chen","doi":"10.3802/jgo.2024.35.e58","DOIUrl":"10.3802/jgo.2024.35.e58","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the cost-effectiveness of tisotumab vedotin to treat recurrent or metastatic cervical cancer in second- or third-line from the U.S. payer perspective.</p><p><strong>Methods: </strong>A Markov model with three-state was employed to simulate recurrent or metastatic cervical cancer patients who were administered either tisotumab vedotin or investigator's choice of chemotherapy based on the phase III, open-labeled innovaTV 301 randomized clinical trial. The data on cost and health preferences were collected from the literature.</p><p><strong>Results: </strong>Tisotumab vedotin generated an additional 0.25 quality-adjusted life-years (QALYs) compared to chemotherapy, but at an additional cost of $206,779. This results in incremental cost-effectiveness ratios of $839,107.88 per QALY. The results of the univariate sensitivity analysis indicated that cost of tisotumab vedotin, utility of progressive disease and progression-free survival had the greatest impacts on the outcomes. Probability sensitivity analysis showed that tisotumab vedotin had a 0% chance of being considered cost-effective.</p><p><strong>Conclusion: </strong>Tisotumab vedotin was unlikely cost-effective compared to chemotherapy for recurrent or metastatic cervical cancer patients at a willingness-to-pay threshold of $150,000/QALY from the perspective of a U.S. payer. Lowering the prices of tisotumab vedotin could potentially enhance its cost-effectiveness.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e58"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11390250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139706961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Step-by-step demonstration of "sciatic-nerve-preserved beyond-LEER" in a Thiel-embalmed cadaver: a novel salvage surgery for recurrent gynecologic malignancies. 逐步演示在泰尔人体模型中进行 "坐骨神经保留外LEER "手术:一种治疗复发性妇科恶性肿瘤的新型挽救手术。
IF 3.9 2区 医学
Journal of Gynecologic Oncology Pub Date : 2024-09-01 DOI: 10.3802/jgo.2024.35.e112
Hiroyuki Kanao,Masato Tamate,Motoki Matsuura,Sachiko Nagao,Miseon Nakazawa,Shutaro Habata,Tsuyoshi Saito
{"title":"Step-by-step demonstration of \"sciatic-nerve-preserved beyond-LEER\" in a Thiel-embalmed cadaver: a novel salvage surgery for recurrent gynecologic malignancies.","authors":"Hiroyuki Kanao,Masato Tamate,Motoki Matsuura,Sachiko Nagao,Miseon Nakazawa,Shutaro Habata,Tsuyoshi Saito","doi":"10.3802/jgo.2024.35.e112","DOIUrl":"https://doi.org/10.3802/jgo.2024.35.e112","url":null,"abstract":"OBJECTIVEComplete resection is the curative treatment choice for recurrent gynecological malignancies. Laterally extended endopelvic resection (LEER) is an effective surgical salvage therapy for lateral recurrence. However, when a recurrent tumor occupies the ischial spine and sacrum, LEER is not indicated, and surgical salvage therapy is abandoned. Theoretically, complete resection of such a tumor is possible by additional pelvic bone resection along with the standard LEER. Nevertheless, owing to the anatomical complexities of the beyond-LEER procedure, 2 major issues should be solved: sciatic nerve injury and tumor disruption during pelvic bone amputation. To overcome these technical challenges, we applied a multidirectional beyond-LEER approach, a novel salvage surgical procedure, with an aim of demonstrating its technical feasibility.METHODSWe created a simulation model of a laterally recurrent tumor that occupied the right ischial spine and sacrum in a Thiel-embalmed cadaver.RESULTSMultidirectional approaches, including laparoscopic, perineal, and dorsal phases, were safely applied. We laparoscopically marked the L4-L5-S1 complex and S2 nerve with different colored tapes, and by pulling them out into a dorsal surgical field, the sciatic nerve was safely preserved. The dissection lines of the multidirectional approaches were aligned using tapes as landmarks, and complete tumor clearance without tumor disruption was accomplished. By following the cadaveric training, the first laparoscopic-assisted beyond-LEER procedure was successfully performed in a patient with recurrent ovarian cancer.CONCLUSIONUsing a Thiel-embalmed cadaver, we demonstrated the technical feasibility of a sciatic nerve-preserved beyond-LEER procedure, which was successfully performed in a patient with recurrent ovarian cancer.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":"33 1","pages":"e112"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142182607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信